Eisai loses DEA battle

Share this article:

Eisai's legal maneuver to pressure the DEA to schedule its FDA-approved epilepsy drug has failed. BioCentury reports that the District of Columbia's US Court of Appeals will not compel the Drug Enforcement Agency to put the seizure medication, Fycompa, on a schedule within a given time frame.

Without a designated schedule, Eisai cannot put the drug on the market, even though the patent life continues to wind down.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions